Bicara Therapeutics (BCAX) Total Liabilities (2023 - 2026)

Bicara Therapeutics has reported Total Liabilities for 4 years, with the latest figure at $39.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 107.33% year-over-year to $39.6 million; the trailing twelve-month figure through Mar 2026 stood at $39.6 million (up 107.33% YoY), and the FY2025 full-year result was $29.5 million, up 63.03% from the prior year.
• Total Liabilities for Q1 2026 stood at $39.6 million, up from $29.5 million in the prior quarter.
• The five-year high for Total Liabilities was $174.8 million in Q2 2024, with the low at $14.6 million in Q3 2024.
• Historically, Total Liabilities has averaged $59.0 million across 4 years, with a median of $21.9 million in 2025.
• Annual changes were most pronounced in 2025 — Total Liabilities tumbled 89.48% — and 2026, when it surged 107.33%.
• Bicara Therapeutics' Total Liabilities stood at $15.5 million in 2023, then climbed by 17.11% to $18.1 million in 2024, then surged by 63.03% to $29.5 million in 2025, then surged by 34.19% to $39.6 million in 2026.
• The last three Total Liabilities figures came in at $39.6 million (Q1 2026), $29.5 million (Q4 2025), and $21.9 million (Q3 2025), per Business Quant data.